Spots Global Cancer Trial Database for Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Official Title: A Randomized Phase II Trial Assessing Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors After Failure of All Drugs Known to be Effective
Study ID: NCT01715441
Study Description
Brief Summary: The aim of this multicenter randomized phase II trial is to determine the efficacy of sorafenib and irinotecan combination versus irinotecan monotherapy or versus sorafenib monotherapy in metastatic colorectal cancer patients with KRAS mutated tumors after failure of all active drugs known to be effective.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hôpital AVICENNE, Bobigny, , France
Centre François Baclesse, Caen, , France
Centre Oscar Lambret, Lille, , France
Centre Léon Bérard, Lyon, , France
Hôpital LA TIMONE, Marseille, , France
CRLC Val d'Aurelle-Paul Lamarque, Montpellier, , France
C.H.U. de REIMS, Reims, , France
CHU Charles Nicolle, Rouen, , France
Institut de Cancérologie de l'Ouest - René Gauducheau, St. Herblain, , France
Contact Details
Name: Emmanuelle SAMALIN, MD
Affiliation: CRLC Val d'Aurelle-Paul Lamarque
Role: PRINCIPAL_INVESTIGATOR
Name: Marc YCHOU, MD,
Affiliation: CRLC Val d'Aurelle
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
